#1 Clinical Trials Search in Europe

Gadoquatrane

Gadoquatrane is an innovative contrast agent being studied for use in magnetic resonance imaging (MRI). This article explores the ongoing clinical trials investigating Gadoquatrane’s safety, effectiveness, and potential advantages over existing contrast agents for improving MRI scans of various body regions.

Table of Contents

What is Gadoquatrane?

Gadoquatrane, also known as BAY1747846, is a new type of contrast agent being developed for use in Magnetic Resonance Imaging (MRI) scans[1]. Contrast agents are substances given to patients before or during an MRI to help create clearer and more detailed images of the inside of the body. This can help doctors better identify and evaluate various health problems.

Gadoquatrane belongs to a class of contrast agents called gadolinium-based contrast agents (GBCAs). These agents contain a rare earth element called gadolinium, which is essential for improving the contrast and signal intensity in MRI scans[2].

How Does Gadoquatrane Work?

When injected into a patient’s vein, Gadoquatrane travels through the bloodstream and into various tissues of the body. The gadolinium in the contrast agent interacts with the magnetic fields used in MRI, causing certain areas of the body to appear brighter or darker on the resulting images. This helps radiologists and doctors see more details and potentially identify abnormalities that might not be visible on a regular, non-contrast MRI[1].

What Conditions Can Gadoquatrane Help Diagnose?

Gadoquatrane is being studied for use in diagnosing a wide range of conditions, including:

  • Brain and spinal cord disorders: Such as tumors, infections, or inflammatory conditions[3]
  • Other body regions: Including organs, soft tissues, and blood vessels throughout the body (except the brain and spinal cord)[4]

The enhanced images provided by Gadoquatrane can help doctors detect, locate, and assess the extent of various abnormalities, potentially leading to more accurate diagnoses and better treatment planning.

Advantages of Gadoquatrane

Researchers are developing Gadoquatrane with several potential advantages over existing contrast agents:

  • Lower gadolinium dose: Gadoquatrane is designed to use a lower amount of gadolinium (0.04 mmol Gd/kg) compared to standard contrast agents (0.1 mmol Gd/kg). This may help reduce the potential risks associated with gadolinium retention in the body[1].
  • Improved image quality: Despite the lower dose, Gadoquatrane aims to provide similar or better image quality compared to existing contrast agents[2].
  • Potential for wider use: Studies are being conducted to evaluate Gadoquatrane’s effectiveness in various body regions, which could make it a versatile option for different types of MRI scans[4].

Current Clinical Trials

Gadoquatrane is currently undergoing several clinical trials to evaluate its safety, effectiveness, and optimal dosing. These studies include:

  • A study in children from birth to under 18 years old to understand how Gadoquatrane moves through the body and assess its safety[1].
  • Trials comparing Gadoquatrane to existing contrast agents for brain and spinal cord imaging[3].
  • Studies evaluating Gadoquatrane for imaging other parts of the body[4].
  • A study in healthy Chinese male participants to assess safety and blood levels of Gadoquatrane at different doses[5].

Safety and Side Effects

As with any medical intervention, researchers are closely monitoring the safety of Gadoquatrane. The ongoing clinical trials are designed to identify any potential side effects or adverse reactions. Common things that doctors look out for include:

  • Injection site reactions
  • Allergic reactions
  • Changes in vital signs (blood pressure, heart rate, body temperature)
  • Any unexpected medical problems that occur after receiving the contrast agent[1]

It’s important to note that as a new contrast agent still in development, the full safety profile of Gadoquatrane is not yet established. The current clinical trials aim to gather more information about its safety in different patient populations.

How is Gadoquatrane Administered?

Gadoquatrane is given as an intravenous injection, which means it’s injected directly into a vein. This is typically done just before or during the MRI scan. The dose is calculated based on the patient’s body weight, with the current studies using a dose of 0.04 mmol Gd/kg body weight[3].

After receiving Gadoquatrane, patients typically undergo the MRI scan, which can last anywhere from 15 minutes to over an hour, depending on the type of scan and the area being examined.

Aspect Details
Drug Name Gadoquatrane (BAY1747846)
Type Gadolinium-based contrast agent (GBCA)
Purpose Enhance MRI scans for better visualization of lesions and pathologies
Dosage 0.04 mmol Gd/kg body weight (typical study dose)
Administration Single intravenous injection during MRI examination
Target Areas Brain, spinal cord, and other body regions
Key Advantage Potential for lower gadolinium dose compared to current GBCAs
Study Populations Adults and children with suspected pathologies; healthy volunteers
Main Outcomes Image quality, lesion detection, diagnostic confidence, safety profile
Comparison Versus approved macrocyclic GBCAs at 0.1 mmol Gd/kg

FAQ

  • What is Gadoquatrane? Gadoquatrane is a new gadolinium-based contrast agent (GBCA) being developed for use in magnetic resonance imaging (MRI). It aims to provide similar or better imaging performance while using a lower amount of gadolinium compared to currently approved contrast agents.
  • How is Gadoquatrane administered? Gadoquatrane is administered as a single intravenous injection, typically at a dose of 0.04 mmol Gd/kg body weight, during or before an MRI examination.
  • What types of conditions is Gadoquatrane being studied for? Clinical trials are investigating Gadoquatrane for enhancing MRI scans of various body regions, including the brain, spinal cord, and other body parts. It is being studied for detecting and evaluating known or suspected lesions and pathologies.
  • How does Gadoquatrane compare to existing contrast agents? Studies are comparing Gadoquatrane at a dose of 0.04 mmol Gd/kg to approved macrocyclic GBCAs at 0.1 mmol Gd/kg. Researchers are evaluating if Gadoquatrane can provide similar or better image quality and diagnostic information while using a lower gadolinium dose.
  • What are the potential benefits of Gadoquatrane? Gadoquatrane aims to provide high-quality contrast-enhanced MRI scans while reducing the amount of gadolinium administered to patients. This could potentially improve the safety profile of contrast-enhanced MRI examinations.

Ongoing Clinical Trials on Gadoquatrane

  • Study on How Gadoquatrane Works and Its Safety in Children Undergoing MRI Scans

    Not yet recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Czechia Germany Hungary Italy Poland +1

  • Study Comparing Gadoquatrane with Gadoteric Acid, Gadobutrol, and Gadoteridol for MRI in Adults with Brain or Spinal Cord Issues

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Germany Hungary Italy +1

  • Study Comparing Gadoquatrane with Gadoteric Acid, Gadoteridol, and Gadobutrol for MRI in Patients with Non-CNS Conditions

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia France Germany Hungary Italy +2

Glossary

  • Gadolinium-based contrast agent (GBCA): A type of contrast medium containing the rare earth element gadolinium, used to enhance the visibility of internal body structures in MRI scans.
  • Magnetic Resonance Imaging (MRI): A medical imaging technique that uses strong magnetic fields and radio waves to generate detailed images of the organs and tissues within the body.
  • Contrast-enhanced MRI (CE-MRI): An MRI examination that uses a contrast agent to improve the visibility of certain tissues or blood vessels.
  • Intravenous injection: The administration of a substance directly into a vein using a needle and syringe.
  • Pharmacokinetics: The study of how a drug moves into, through, and out of the body, including its absorption, distribution, metabolism, and excretion.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Blinded study: A type of clinical trial where participants, researchers, or both are unaware of which treatment is being administered to reduce bias.
  • Central Nervous System (CNS): The part of the nervous system consisting of the brain and spinal cord.
  • Lesion: Any abnormality in the tissue of an organism, usually caused by disease or trauma.
  • Macrocyclic GBCA: A type of gadolinium-based contrast agent with a molecular structure that forms a cage around the gadolinium ion, potentially improving its stability and safety profile.

References

  1. https://clinicaltrials.gov/study/NCT05915026
  2. https://clinicaltrials.gov/study/NCT04307186
  3. https://clinicaltrials.gov/study/NCT05915702
  4. https://clinicaltrials.gov/study/NCT05915728
  5. https://clinicaltrials.gov/study/NCT06135181